The trial aimed to evaluate the impact of adding a once-daily treatment to standard care to reduce cardiovascular deaths and heart failure-related events in patients with impaired kidney function.
Hightower Clinical’s previous study on heart failure and impaired kidney function contributed to more effective care strategies and helped improve the quality of life for many patients.
Heart failure occurs when the heart can’t pump blood effectively, leading to symptoms like fatigue, shortness of breath, and swelling. Chronic kidney disease (CKD), a gradual loss of kidney function, often contributes to heart failure by increasing strain on the heart and disrupting fluid and blood pressure balance.
To better understand this connection, Hightower conducted a clinical trial focused on heart failure and impaired kidney function. The study evaluated the effects of a once-daily treatment added to standard care on reducing cardiovascular death and heart failure-related events.
Not Recruiting
01
Study Name | Protocol Number | Sponsor |
---|---|---|
Heart Failure & Impaired Kidney Function | BalanceD-HF | AstraZeneca |
The trial aimed to evaluate the impact of adding a once-daily treatment to standard care to reduce cardiovascular deaths and heart failure-related events in patients with impaired kidney function.
Adults diagnosed with heart failure and chronic kidney disease (CKD) were enrolled to assess how the treatment affected outcomes related to both conditions.
No, the study is not recruiting at this time.